节点文献

吉西他滨联合顺铂治疗中晚期非小细胞肺癌临床近期疗效观察

The treatment with Gemcitabine combined and Cisplatin in the intermediate-advanced stage of non-small cell lung cancer

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 舒守宏方平

【Author】 SHU Shouhong,FANG Ping(Department of Respiratory Medicine,Tongling People’s Hospital,Tongling 244000,China)

【机构】 安徽省铜陵市人民医院呼吸内科

【摘要】 目的:观察国产吉西他滨(GEM,泽菲)联合顺铂(PDD)组成的GP方案治疗中晚期非小细胞肺癌(NSCLC)的疗效及毒副作用。方法:42例经病理或细胞学证实的中晚期非小细胞肺癌患者,采用GP方案化疗,GEM1000mg/m2第1天、第8天静滴,PDD80mg/m2第1天静滴,21d为1个周期,使用2~4个周期。结果:42例中,完全缓解(CR)2例(4.76%),部分缓解(PR)17例(40.48%),稳定(SD)14例(33.33%),进展(PD)9例(21.42%),客观有效率(RR=CR+PR)为45.24%(19/42)。毒副作用主要表现为血白细胞、血小板下降,恶心呕吐等,但均可耐受。结论:吉西他滨联合顺铂治疗中晚期非小细胞肺癌有较好的疗效,毒副作用可耐受,值得临床推广应用。

【Abstract】 Objective:To observe the therapeutic effect and side effect of Gemcitabine combined and Cisplatin in the intermediate-advanced stage of non-small cell lung cancer(NSCLC).Methods:42 patients with advanced NSCLC enrolled in allotted to the study.The patients were treated with GP regiment,GEM 1 000 mg/m2,dl and d8 intravenous infusion.PDD 80 mg/m2 d1 intravenous infusion.21 days for one cycle,all patients received 2-4 cycles therapies.Results:In 42 cases,CR 2 cases(4.76%),PR 17 cases(40.48%),SD 14 cases(33.33%),PD 9 cases(21.42%),RR(CR+PR) was 45.24%(19/42).The main side effects were leucopoenia,thrombocytopenia,gastro-intestinal reaction.Conclusion:Gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer have better efficacy,side effects can be tolerated,it is worth clinical application.

  • 【文献出处】 中国医药导报 ,China Medical Herald , 编辑部邮箱 ,2009年21期
  • 【分类号】R734.2
  • 【下载频次】43
节点文献中: 

本文链接的文献网络图示:

本文的引文网络